Get the Stockscreener App
0.0001
2.94%
-0.1019
Neximmune Inc stock is traded at $0.0001, with a volume of 0.
It is down -2.94% in the last 24 hours and down -22.22% over the past month.
See More
Previous Close:
$0.102
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-20.62M
P/E Ratio:
-0.000005
EPS:
-18.54
Net Cash Flow:
$-17.61M
1W Performance:
-2.94%
1M Performance:
-22.22%
6M Performance:
-74.07%
1Y Performance:
+623.57%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Neximmune Inc Stock (NEXI) Company Profile
Compare NEXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEXI
Neximmune Inc
|
0.00 | 0 | 0 | -20.62M | -17.61M | -18.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.51 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.89 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.60 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
261.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neximmune Inc Stock (NEXI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-21 | Initiated | Raymond James | Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Mar-09-21 | Initiated | Cantor Fitzgerald | Overweight |
Neximmune Inc Stock (NEXI) Latest News
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Analyzing Theratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz
Vanotech appoints Matthew Schiller to Lead Business Development - EFECOMUNICA
Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World
NexImmune (NASDAQ:NEXI) Stock Price Down 15.2% – Should You Sell? - Defense World
North American Morning Briefing : Tesla, Chip -2- -January 03, 2025 at 06:08 am EST - Marketscreener.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.76% - MSN
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace
NexImmune moves forward with wind-down process - The Business Journals
NexImmune shareholders approve company dissolution - Investing.com
What Are the Rules Behind the Delisting of a Stock? - Investopedia
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
NexImmune Faces Critical Funding Crisis, Mulls Liquidation - TipRanks
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - InvestorPlace
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
NexImmune's future in limbo as Gaithersburg biotech extends liquidation vote - The Business Journals
NEXI Stock Halted: What’s Going on With NexImmune Shares Today? - InvestorPlace
Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq - The Business Journals
D.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuit - The Business Journals
NexImmune (NASDAQ: NEXI) to jump 2,500% todaya purely technical move - Dhaka Tribune
NexImmune to lay off over half of its employees - Pharmaceutical Technology
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy - Stock Titan
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT). - ASCO Publications
Sirnaomics spinout RNAImmune launching clinical trial for Covid-19 vaccine booster - The Business Journals
Gaithersburg biotech Salubris Biotherapeutics clinches $35M investment for R&D - The Business Journals
Silver Spring's Aziyo Biologics laying off 12% of workforce - The Business Journals
Why NexImmune (NEXI) Shares Are Trading Higher TodayNexImmune (OTC:NEXI) - Benzinga
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’ - insights.citeline.com
AIM™ platform: A new immunotherapy approach for viral diseases - Frontiers
Biotechs reveal layoffs, research revamps in third quarter earnings - BioPharma Dive
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders - Business Wire
Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies - GlobeNewswire
Global Human Papillomavirus Associated Cancer Pipeline - GlobeNewswire
Zephyr AI Announces Additions to the Board of Directors - Business Wire
Pharma50: 50 Leading Cell and Gene Therapy Companies - drugdiscoverytrends.com
What Makes NexImmune, Inc. (NEXI) a New Buy Stock - Nasdaq
NexImmune Appoints Dr. Leena Gandhi To Board - citybiz
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer - The Globe and Mail
D.C. Council member ends effort to reinstate proof of vaccination requirement to enter businesses - The Business Journals
NexImmune Appoints Kristi Jones as CEO - citybiz
Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product - Business Wire
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. - The Business Journals
Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program - Business Wire
Neximmune Inc Stock (NEXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.26%
Cap:
|
Volume (24h):